EEElena A. Enina

Elena A. Enina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena A. Enina has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epithelial‑T‑cell axis cytokines and vitamin D status in different asthma phenotypes in children

    by S. V. Dolbnya, V. R. Ponamaryova, I. N. Zakharova, L. Ya. Klimov, A. A. Tolkunova, L. Yu. Barycheva, V. V. Kuznetsova, E. A. Enina, N. A. Fedko, N. V. Zaritovskaya, et al.

    Introduction. Bronchial asthma (BA) is a heterogeneous disease that manifests in various phenotypes; identifying these phenotypes allows for the individualization of treatment, which is particularly important among pediatric patients. Aim . To determine the role of IL-17A and IL-33 in identifying bronchial asthma phenotypes in children receiving prophylactic cholecalciferol. Material and methods . A total of 156 children and adolescents from the Stavropol Krai with asthma, aged 13.5 [10.0; 15.9] years, were studied. During the period 2024–2025, a two-stage study of vitamin D status and IL-17A and IL-33 levels was conducted in children against the background of a 3-month intake of an aqueous solution of cholecalciferol at a dose of 1000 IU/day. Results . We identified three main asthma phenotypes in the study group: atopic asthma – 125 (80.1%), non-atopic asthma – 9 (5.8%), and asthma associated with obesity – 22 (14.1%). Statistically significant differences were found only in parameters determining the patients’ phenotypic classification: total IgE level (p = 0.016) and age-adjusted BMI SDS (p < 0.001). No significant differences in serum calcidiol, IL-17A, and IL-33 levels were observed depending on the phenotype. No significant differences in serum calcidiol, IL-17A, and IL-33 levels were observed across phenotypes; however, there was a trend toward lower vitamin D levels and higher cytokine levels as asthma severity increased. Against the background of a prophylactic course of CC medication, a significant increase in vitamin D sufficiency was observed (p < 0.001), which was accompanied by a decrease in IL-17A levels (p = 0.002). No significant effect on IL-33 levels was detected. Conclusion . A three-month course of prophylactic cholecalciferol supplementation leads to a significant reduction in vitamin D deficiency in children and adolescents with asthma and a decrease in IL-17A levels; when combined with standard stepwise therapy, it improves disease control.

  • Open Access

    Efficacy and safety of switching within one international non-proprietary name (elexacaftor/tezacaftor/ivacaftor) in children with cystic fibrosis: clinical experience of transition from Trikafta to Trilexa

    by D. F. Sergienko, O. I. Golubtsova, E. A. Enina, Д. Ф. Сергиенко, О. И. Голубцова, Е. А. Енина

    Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane regulator gene and is accompanied by chronic damage to the respiratory and gastrointestinal systems. Triple therapy with elexacaftor, tezacaftor, and ivacaftor significantly improves lung function and nutritional status. However, the high cost of the original drugs limits long-term use, making the use of bioequivalent generics such as Trilexa® relevant. Objective: To evaluate the efficacy and safety of switching from the original triple therapy (Tricafta®) to the generic drug Trilexa® in children with cystic fibrosis in a real-world clinical setting. Materials and methods: Data from 28 children aged 6–18 years (14 boys, 14 girls; median age 13.0 years (11.8–15.0)) with confirmed cystic fibrosis, treated with Trikafta® for 2–36 months and transferred to Trilexa® with a subsequent 180-day observation were analyzed. Body mass index, forced expiratory volume in the first second, forced vital capacity (% of predicted), and sweat chloride concentration were assessed; statistical processing was performed using the Wilcoxon test ( p < 0.05). Results: the median body mass index increased from 17.6 to 17.7 kg/m² ( p = 0.077), with 75.0 % of patients showing an improvement or stabilization of the indicator. Forced expiratory volume in the first second increased from 93.5 to 95.0 % of the predicted value ( p = 0.220), forced vital capacity – from 95.5 to 99.5 % ( p = 0.025), the proportion of children with forced vital capacity ≥ 100 % increased from 50.0 to 64.3 %. Sweat chloride concentration remained stable (47.5 and 50.5 mmol/L; p = 0.875); no serious adverse reactions were recorded, all patients continued therapy at the full dose. Conclusion: the switch from Trikafta® to Trilexa® in children with cystic fibrosis does not lead to the loss of the achieved clinical effects, is accompanied by the preservation of nutritional status, stability of external respiratory function and sweat test parameters, and is characterized by a favorable safety profile.

  • Open Access

    Effectiveness of correction of hypovitaminosis D against the background of standard step therapy of bronchial asthma in children

    by S. V. Dolbnya, V. R. Ponamaryova, I. N. Zakharova, L. Ya. Klimov, A. A. Tolkunova, L. Yu. Barycheva, V. V. Kuznetsova, E. A. Enina, N. N. Zaritovskaya

    Introduction. The close interest of a wide range of pediatricians in the problems of bronchial asthma (BA) is due to its prevalence, difficulties in selecting basic therapy, and the high frequency of hypovitaminosis D.Aim. To analyze the frequency of vitamin D deficiency and the effectiveness of its correction by including cholecalciferol preparations in the standard step therapy regimen for bronchial asthma in children.Materials and methods. The study involved 75 children and adolescents from the Stavropol Territory suffering from BA, aged12.4 [9.5; 14.8] years. From 2018 to 2021, a two-stage study of vitamin D status was conducted in patients – initially and after completion of a 3-month intake of cholecalciferol aqueous solution (CCF).Results. At the 1st stage of treatment, all 3 (100%) patients were over 12 years old and received low doses of ICS each time they used SABA without constant basic therapy. At the 2nd stage of therapy, all 9 (100%) patients used LRA drugs in age-appropriate dosages. At the 3rd stage, 1 (5.3%) child received treatment with medium doses of ICS, 10 (52.6%) children used a fixed combination of ICS-LABA, and 8 (42.1%) a combination of ICS + LRA.The vitamin D status after taking cholecalciferol preparations increased from 18.3 ng/ml to 35.4 ng/ml. Vitamin D deficiency was initially detected in 44 (58.7%) children, and after the correction course – only in 3 (4.0%) people (p < 0.001).Initially, the median AST was 16.0 [12.0; 20.5] points, and at the end of the study 20.0 [16.0; 24.0] points (p < 0.004).Conclusion. Step therapy for asthma should be prescribed in according to current clinical guidelines. ICS should be used more widely as initial basic therapy for asthma, reducing the number of people receiving monotherapy with ALR.


  • Clinical case report of the combined spondylocostal dysostosis-4 (Jarcho-Levin syndrome) and Sifrim-Hitz-Weiss syndrome in a newborn

    by L.YA. Klimov, N.YE. Verisokina, T.M. Vdovina, ” Stavropol Autonomous Non-Profit Medical Organization “Stavropol Krai Regional Clinical Consultative And Diagnostic Center, E.S. Ludanova, R.A. Zhetishev, T.V. Zheleznyakova, E.A. Tovkan, Stavropol Stavropol Krai Regional Children'S Clinical Hospital, A.V. Kastarnov, et al.

    Spondylocostal dysostosis is a rare hereditary disease that is accompanied by a violation of the segmentation of the spine. The features of the appearance of patients are characterized by spondylocostal dysplasia in the form of a shortened neck and a “crab-shaped” deformation of the chest due to the fusion of the distal and divergence of the proximal ribs. It belongs to orphan genetic diseases, Worldwide frequency of which is 1:200,000 newborns. To date, six genetic variants of this disease with different types of inheritance have been described as follows: autosomal recessive forms associated with the genes DLL3, MESP2, LFNG, HES7 (spondylocostal dysplasia-1), autosomal dominant form with the TBX6 gene (spondylocostal dysplasia-2), the inheritance of changes in the RIPPLY2 gene has not been established. Since the syndrome is a disease with low prevalence, patients need various diagnostic and screening tests with interdisciplinary evaluation of the results at different stages of their life. Early diagnosis of the disease is crucial for timely treatment and rehabilitation measures and further improvement of the quality-of-life prognosis for the child. Authors represent a clinical case of genetically confirmed spondylocostal dysostosis-4 in a child, during the examination of which a previously undescribed pathogenic variant of the nucleotide sequence in exon 4 of the HES7 gene in a homozygous state, a Sifrim-Hitz-Weiss syndrome, was detected. The presented clinical case is of a particular practical interest to geneticists, radiation diagnosticians, obstetricians-gynecologists and neonatologists in the context of the timely diagnosis problematics.

  • Open Access

    The effect of cholecalciferol subsidies on the level of pro-inflammatory cytokines in children with bronchial asthma

    by S. V. Dolbnya, A. A. Tolkunova, I. N. Zakharova, V. R. Ponamaryova, L. Ya. Klimov, L. Yu. Barycheva, N. V. Zaritovskaya, V. V. Kuznetsova, E. A. Enina

    Introduction. Currently, there are insufficient studies to demonstrate the effect of vitamin D status on the production of proinflammatory cytokines in children with allergic diseases, which precipitated this study.Aim. To analyse interferon-γ, interleukin-17A and 33 profiles in children with asthma according to serum calcidiol levels before and during cholecalciferol subsidies.Materials and methods. A total of 71 children aged 3 to 18 years were examined: 51 patients with asthma and 20 children in the control group. A 3-month cholecalciferol course at a prophylactic dose specified in the national program was prescribed to all children. 25(OH)D, interferon-γ, interleukin-17A and 33 levels were twice determined in the examined children.Results and discussion. Median 25(OH)D levels in patients with asthma did not reach the levels of healthy children either before or after cholecalciferol subsidies at prophylactic doses. Vitamin D intake led to a decrease in interferon-γ levels in healthy children from 3.07 [2.29; 4.81] pg/ml to 2.18 [1.74; 3.45] pg/ml (p < 0.05). In patients with asthma, such changes were not detected in the initial population, however, after cholecalciferol subsidies their interferon-γ levels were significantly higher than those in healthy children: 3.11 [0.89; 5.0] pg/ml and 2.18 [1.74; 3.45] pg/ml, respectively (p < 0.05). Assessment results of interleukin-17A levels in children with asthma showed that the median cytokine levels were significantly higher before the cholecalciferol subsidies than after them: 2.03 [0.1; 10.01] pg/ml and 0.96 [0.1; 12.87] pg/ml, respectively (p = 0.03). The median interleukin-17A levels in children with asthma were significantly higher than in healthy children, both before and during the cholecalciferol subsidies. The median interleukin-33 levels were significantly higher in children with asthma as compared to healthy children, both before and during vitamin D subsidies.Conclusion. Our results suggest that cholecalciferol has a modulatory effect on interferon-γ and interleukin-17A in patients with asthma. Interleukin-33 levels did not change significantly in children with asthma on cholecalciferol.


  • Relationship between vitamin D sufficiency and interferon-γ levels in children with chronic lung diseases

    by S. V. Dolbnya, A. A. Dyatlova, L. Ya. Klimov, E. I. Kondratyeva, I. N. Zakharova, E. A. Enina

    Introduction. The role and mechanism of the effect of vitamin D on the course of chronic lung diseases in children are not yet fully understood. In particular, there are not enough studies on the effect of vitamin D status on the production of interferon-γ (IFN-γ) in children with cystic fibrosis and bronchial asthma.Aim. To analyse the changes in IFN-γ levels in children with cystic fibrosis and bronchial asthma according to the serum 25(OH)D level before and during cholecalciferol supplementation.Materials and methods. A total of 114 children (aged from 3 months to 18 years old) were examined, including 51 (44.7%) children with bronchial asthma, 34 (29.8%) children with cystic fibrosis, and 29 (25.5%) children of the control group. If hypovitaminosis D was diagnosed, the children received a three-month cholecalciferol course at doses in accordance with the recommendations of the national consensus - Cystic Fibrosis: Definition, Diagnostic Criteria, Therapy and the national program - Vitamin D Deficiency in Children and Adolescents of the Russian Federation: Current Approaches to Management. The 25(OH)D and IFN-γ levels were twice determined in all children.Results. Median 25(OH)D levels in patients with cystic fibrosis and bronchial asthma did not reach the level of healthy children either before or after supplementation with cholecalciferol drugs at the recommended doses. Vitamin D intake resulted in a decrease in IFN-γ levels in healthy children from 3.07 [2.29; 4.81] pg/ml to 2.18 [1.74; 3.45] pg/ml (p < 0.05), whereas such changes were not detected in the paediatric patients with cystic fibrosis and bronchial asthma in the general population. However, after supplementation with cholecalciferol, the IFN-γ level was significantly higher in patients with cystic fibrosis and bronchial asthma - 2.86 [2.13; 3.86] pg/ml and 3.11 [0.89; 5.0] pg/ml, respectively, than in healthy children - 2.18 [1.74; 3.45] pg/ml (p < 0.05). A statistically significant decrease in IFN-γ level was observed in girls with cystic fibrosis and in healthy girls after supplementation with cholecalciferol, whereas no significant changes in IFN-γ levels were detected in the groups of boys.Conclusion. Modulation of IFN-γ levels appears to be one of the mechanisms of immunotropic effect of vitamin D on the course of chronic inflammation of infectious (cystic fibrosis) and allergic (bronchial asthma) etiology in children.


  • Open Access

    Characteristics of mukoviscisidosis in the southern regions of Russia

    by E. I. Kondratieva, S. V. Trishina, A. V. Yurieva, N. V. Komlev, V. A. Tanaga, V. A. Terentiev, A. Yu. Voronkova, E. L. Amelina, A. V. Chernyak, S. A. Krasovskiy, et al.

    Introduction. Cystic fibrosis (CF) is a hereditary disease with genetic heterogeneity and clinical polymorphism. Expanding the range of knowledge about the characteristics of the course of the disease in different regions is important to achieve the goal of improving the quality and life expectancy.Purpose. Comparative analysis of the features of the course of CF in the subjects of the Southern Federal District, Stavropol Territory.Methods. Data from the National Register of Patients of the RF MV 2016 were used. Results: there are clinical and genetic features between the regions of the Southern Federal District and the Stavropol Territory of the North Caucasus Federal District and in general with the Russian Federation. Analysis of the data showed differences in indicators: the proportion of patients aged ≥ 18 is the lowest in the Republic of Crimea (14.9%), in the Rostov region the lowest average age of patients (9.0 ± 6.3), and the lowest age of diagnosis 2.2 ± 3.1 years. Late terms of diagnosis were revealed in the Stavropol Territory (4.0 ± 8.0 years), but here there is one of the highest average age of CF patients (14.1 ± 11.5), the proportion of adult patients (23.3%) and the lowest allelic frequency of F508del, which is determined by the high number of patients with a “soft” genotype. There is a high proportion of patients with an undetermined genotype. A low proportion of two identified genetic variants of the CFTR gene is registered in patients of the Republic of Crimea. A low frequency of Burkholderia cepacia complex and Achromobacter spp was revealed, and a high infection with non-tuberculous mycobacteria was revealed in the Rostov region. FEV1 in children and adults was lower in Rostov Region and Stavropol Territory. In all regions, there is a discrepancy between the seeding of flora and azithromycin therapy and the severity of the genotype with the use of pancreatic enzymes.Conclusions. Analysis of the data of the registry, which allows substantiating the need to study the regional characteristics of the course of CF in order to differentiate the planning of measures to improve the quality of medical care for patients with CF.

  • Open Access

    Role of vitamin D in pre-school children’s health

    by Irina N. Zakharova, Svetlana V. Dolbnya, Victoriya A. Kuryaninova, Leonid Ya. Klimov, Shamil O. Kipkeev, Anna N. Tsutsaeva, Anastasia V. Yagupova, Elena A. Enina, Liana L. Avtandilyan, Roza A. Atanesyan, et al.

    Vitamin D has pleiotropic effects, including maintaining calcium and phosphate homeostasis, and affecting the immune and endocrine systems. The article summarizes data on the expected biological effects of vitamin D on children’s health. The results of randomized clinical trials evaluating the effect of vitamin D supplementation on the incidence of acute respiratory tract infections are reviewed in detail. It has been shown that daily intake of vitamin D at a dose of 10 to 25 mcg/day (400–1000 IU/day) compared with placebo leads to a significant decrease in the proportion of children and adolescents who have had at least one episode of acute respiratory infection. The criteria for the provision of calciferol and the gradation of the status of vitamin D deficiency and deficiency in different countries are discussed. It has been shown that in the interpretation of the 25 (OH) D results there is a consensus on two points: calcidiol levels below 12 ng/ml (30 nmol/L) are considered clearly insufficient, and levels above 30 ng/ml (75 nmol/L) are considered sufficient in all regions. The incidence of hypovitaminosis D has been reported in children aged 3 to 7 years, where the overall combined assessment, regardless of age group, ethnic composition and breadth of the studied populations, showed that 13% of European children had a serum calcidiol concentration of less than 12 ng/ml (<30 nmol/L), and about 40% had a level of less than 30 ng/ml (<75 nmol/L). The data on the physiological need and the recommended daily dose of vitamin D for preschool children have been analyzed. In each country, the recommended intake of vitamin D is set (from 400 to 4000 IU), depending on the target concentration of serum calcidiol, the level of insolation, and nutritional characteristics. The necessity of conducting clinical studies in the age group from 3 to 7 years to determine an adequate, effective and safe preventive dose of vitamin D for preschool children in the Russian Federation is emphasized.

  • Open Access

    259 National cystic fibrosis patients Registry of Russia (RCFPR) in 2014

    by E. Amelina, S. Krasovsky, A. Cherniak, N. Kashirskaya, E. Kondratieva, A. Voronkova, Y. Gorinova, I. Alimova, I. Asherova, G. Baykova, et al.